Volunteer in Oxford-AstraZeneca COVID-19 vaccine trial dies in Brazil; officials say testing to continue

Oxford confirmed the plan to keep testing, saying in a statement that after careful assessment 'there have been no concerns about safety of the clinical trial'

Agence France-Presse October 22, 2020 09:29:16 IST
Volunteer in Oxford-AstraZeneca COVID-19 vaccine trial dies in Brazil; officials say testing to continue

Representational image.

Rio de Janeiro: A volunteer participating in clinical trials of the COVID-19 vaccine developed by Oxford University has died in Brazil, officials announced Wednesday, though media reports said he had received a placebo, not the test vaccine.

It is the first death reported in the various coronavirus vaccine trials taking place worldwide.

However, organizers of the study said an independent review had concluded there were no safety concerns and that testing of the vaccine, developed with pharmaceutical firm AstraZeneca, would continue.

Media reports said the volunteer was a 28-year-old doctor working on the front lines of the pandemic who died of complications from COVID-19 .

Brazilian newspaper Globo and international news agency Bloomberg said he was in the control group and had received a placebo rather than the test vaccine, citing sources close to the trials.

"Following careful assessment of this case in Brazil, there have been no concerns about safety of the clinical trial, and the independent review in addition to the Brazilian regulator have recommended that the trial should continue," Oxford said in a statement.

AstraZeneca said medical confidentiality meant it could not give details on any individual volunteer, but that independent review had "not led to any concerns about continuation of the ongoing study."

Brazil's national health regulator, Anvisa, confirmed it had been notified of the case on 19 October.

The D'Or Teaching and Research Institute (IDOR), which is helping organize the tests in Brazil, said the independent review had "raised no doubts about the safety of the study, and recommended it continue."

Oxford and AstraZeneca previously had to suspend testing of the vaccine in September when a volunteer in Britain developed an unexplained illness.

Trials resumed after British regulators and an independent review concluded the illness was not a side effect of the vaccine.

Half the volunteers in the final-stage clinical trial - a double-blind, randomized, controlled study - receive a placebo, IDOR said.

Around 8,000 volunteers have been vaccinated so far in Brazil, and more than 20,000 worldwide, it said.

Study participants must be doctors, nurses or other health sector workers who come into regular contact with the virus.

The deceased volunteer was a young doctor who had been treating COVID-19 patients since March in the emergency rooms and intensive care units at two hospitals in Rio de Janeiro, Globo said.

He graduated from medical school last year, and was in good health prior to contracting the disease, family and friends told the newspaper.

Updated Date:

also read

Omicron COVID-19 variant is a cause for concern, not panic: US President Joe Biden tells Americans
World

Omicron COVID-19 variant is a cause for concern, not panic: US President Joe Biden tells Americans

When omicron arrives, and it will, Biden said, America will “face this new threat just as we’ve faced those that have come before it.”

‘Mixing AstraZeneca, Pfizer vaccines with Moderna or Novovax generates better response against COVID-19’
Health

‘Mixing AstraZeneca, Pfizer vaccines with Moderna or Novovax generates better response against COVID-19’

The study at the University of Oxford in the UK found that no safety concerns were raised in the study of 1,070 participants

Nirmala Sitharaman says 'Indians resilient, can adapt to any situation', but urges caution over Omicron
India

Nirmala Sitharaman says 'Indians resilient, can adapt to any situation', but urges caution over Omicron

The finance minister said there needs to be a sense of caution about the new variant, and protocols need to be followed. Sitharaman was speaking at the Hindustan Times Leadership Summit on Saturday